Navigation Links
Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer
Date:9/2/2008

SOUTH SAN FRANCISCO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that William Houghton, M.D. has joined the company as senior vice president and chief medical officer. Dr. Houghton will lead Anesiva's clinical and regulatory functions.

"Bill brings to Anesiva deep commercial and product development expertise with pain management products, and a medical background in anesthesiology," said Mr. Kranda. "He fills a key role as we proceed with the clinical development of Adlea for the management of acute pain following orthopedic surgeries, pursue approval of the adult indication for Zingo, and evaluate strategies to increase the clinical and commercial potential of these products. I also look forward to working with Bill to evaluate opportunities to expand Anesiva's portfolio of pain management products."

Dr. Houghton has more than 20 years of clinical development and regulatory affairs experience. Prior to joining Anesiva, he was chief medical officer of Eleos, Inc., a private company. From 2005 to 2007 he was vice president, clinical and regulatory affairs for Alexza Pharmaceuticals, Inc., where he was responsible for the development and conduct of clinical trials for a novel Fentanyl formulation, among others. From 1998 to 2005, Dr. Houghton was associated with Orphan Medical, Inc., where he directed regulatory and clinical development strategies, and provided scientific support of commercialized products. He began his career in industry with Abbott Laboratories, Inc. in 1984 where he worked until 1995. Most recently, from 1992 to 1995, he was medical director of Abbott's hospital products division, providing medical support to the business units for anesthesia and pain management, i
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
(Date:8/27/2014)... After the boom of the energy drink ... craze is going to be the stress relief drinks. ... Stress Relief energy pattern which can be applied to ... beverage, including minerals, herbs and liquids. Stress Relief generates ... into rapid recovery and helping to adapt more quickly. ...
(Date:8/27/2014)... Hunting Valley, Ohio (PRWEB) August 27, 2014 ... five students from Cleveland's University School ... at Case Western Reserve University’s School of ... program provides students with an unparalleled professional experience ... with the School of Medicine faculty and students ...
(Date:8/26/2014)... 26, 2014 An analysis by Replikins, Ltd. ... Mers CoV virus strains has revealed extensive ... 2012.  This conservation and sharing of specific Replikin gene ... Blocker-Vaccine™ candidate, as it did for the H5N1 influenza ... which have been found to be effective (1,2). ...
Breaking Biology Technology:Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... Still Earn D,s or F,s on ... Legislation Report Card, WASHINGTON, March 11 For the ... laws that,require insurance providers to cover the cost of colon cancer screening,tests, according ... groups. The enactment of new coverage laws in five states,during 2007 also increased ...
... 11 Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ... PBI,s senior executive management team as Vice President,of ... years of experience in,sales and sales management at ... will oversee PBI,s seven US-based, regional sales directors ...
... an Interferon-Beta Therapy, According to a New Report from Decision ... ... Mass., March 11 Decision Resources, one of the,world,s leading research ... Pharmaceutical,s Copaxone has the,greatest patient share among first- and second-line therapies, ...
Cached Biology Technology:Colon Cancer Screening Laws Now Cover Half of U.S. Population 2Colon Cancer Screening Laws Now Cover Half of U.S. Population 3Colon Cancer Screening Laws Now Cover Half of U.S. Population 4Colon Cancer Screening Laws Now Cover Half of U.S. Population 5Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 2Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 3Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 4Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html ... to assess individuals on the basis of their ... and identification of both physiological traits such as ...
(Date:8/27/2014)... easier when it only requires nerve cells to rearrange ... have to generate new patterns, a study of monkeys ... learn through recordings of electrical activity of brain cell ... Institutes of Health. , "We looked into the brain ... think outside the box," said Aaron Batista, Ph.D., an ...
(Date:8/27/2014)... LAKE CITY, Aug. 27, 2014 University of Utah ... his native Turkey, has won that nation,s highest science ... of Science. , Sekercioglu is among five researchers picked ... and Technical Research Council of Turkey. Three researchers won ... won the Special Award, which is equivalent to the ...
Breaking Biology News(10 mins):Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5Scientists plug into a learning brain 2Scientists plug into a learning brain 3University of Utah biologist wins Turkey's top science prize 2
... Ill., Nov. 15 Corporate Safe Specialists (CSS),announces ... The,Company has hired Randy Biela, a software engineer, ... http://www.newscom.com/cgi-bin/prnh/20070119/CGF030LOGO ) Ed McGunn, President and CEO ... department of five full-time employees led by myself. ...
... dogs and humans display many of the same characteristics, ... breast cancer progression and prevention for people and pets, ... Veterinary Medicine. A group of scientists including Sulma ... considered to carry risk for developing breast cancer in ...
... do immobile organisms like plants cope when faced with ... question in light of new environmental conditions brought on ... study, published in the Nov. 16 issue of the ... setting as their maternal plant performed almost 3 times ...
Cached Biology News:Corporate Safe Specialists Announces Additions to R&D Team 2Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 2Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 3Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 4Evolutionary biology research on plant shows significance of maternal effects 2
... the efficient enrichment of functional endoplasmic ... cell culture. The isolated ER are ... metabolic pathway analysis. Metabolic abnornalities of ... children, cystic fibrosis and many more ...
Plasmid expressing PLAP reporter gene....
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: